VetDC Announces Commercial Launch Of TANOVEA-CA1 For Lymphoma In Dogs

FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today announced that TANOVEA™-CA1 (rabacfosadine for injection) is now commercially available in the US for purchase by licensed veterinarians. TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs.

“Based on our first-hand experience as part of a robust clinical trials program, we believe TANOVEA-CA1 has the potential to become a cornerstone for the treatment of lymphoma in dogs.”

“VetDC stands out among an elite group of pure-play animal health startups that have advanced a novel program from development through commercialization”, stated Dr. Terry Opgenorth, Vice President of CSU Ventures and VetDC co-founder. “We believe TANOVEA-CA1 represents a significant breakthrough in the rapidly evolving field of veterinary oncology.”

“We are ecstatic to hear the news of TANOVEA-CA1’s commercial availability”, noted Dr. Craig Clifford, a board-certified veterinary oncologist and clinical investigator at Hope Veterinary Specialists in Malvern, PA. “Based on our first-hand experience as part of a robust clinical trials program, we believe TANOVEA-CA1 has the potential to become a cornerstone for the treatment of lymphoma in dogs.”

TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma. TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile. TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.

TANOVEA-CA1 is conditionally approved by the FDA for the treatment of canine lymphoma pending a full demonstration of effectiveness. It is a violation of Federal Law to use this product other than as directed in the labeling.

For additional prescribing, safety, and ordering information, please visit tanovea.com.

Important Safety Information: In dogs treated with TANOVEA-CA1, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Please see the package insert for additional warnings, precautions, and contraindications.

About VetDC, Inc.
VetDC (www.vetdc.com), a Colorado State University startup company, is dedicated to bringing innovative pet cancer therapeutics to market. In addition to TANOVEA-CA1 for canine lymphoma, VetDC is developing VDC-597, a novel, dual-acting PI3K/mTOR inhibitor, for multiple veterinary cancers, such as hemangiosarcoma and osteosarcoma.